Objective: The aim of this study is to investigate the use of Tc-MIBI imaging after successive increases in the therapeutic dose of 131 I, and the serum levels of thyroglobulin (Tg)
were measured.
Results: A total of 191 patients were enrolled in the final analysis, including 65 metastases and/or thyroid remnant-positive patients (22 patients with metastases and 43 patients with thyroid remnants). The sensitivity of 99m Tc-MIBI imaging for detecting positive cases and thyroid remnants was 56.9% and 39.5%, respectively, which was significantly lower than that of 131 I imaging (92.3% and 100%, respectively, P,0.01 for both). The sensitivity of Tc-MIBI imaging for detecting metastases was 90.9%, which was slightly higher than that of 131 I imaging (77.3%, P.0.05). The Tg levels in the positive group were significantly higher than that in the negative group (P,0.01). In addition, the Tg levels in the Tc-MIBI imaging was able to detect the existence of metastatic lesions in patients with DTC better, its assessment for the removal efficiency of thyroid remnants was unsatisfactory. The results of
Introduction
Thyroid cancer (TC), the most common malignant tumor among endocrine and head-neck tumors, with an increasing incidence in recent years, accounts for ~3% of all malignancies. 1 Differentiated thyroid cancer (DTC) accounts for .90% of all TC cases. Currently, the routine treatment for DTC is surgery plus 131 I therapy plus thyroid-stimulating hormone (TSH) suppression therapy. 2, 3 Total or near-total thyroidectomy is the most commonly used surgical procedure.
131
I therapy includes the ablation of thyroid remnants and local/distant metastases with the postoperative use of different activities of 131 I. The suppression of TSH using supraphysiologic doses of levothyroxine to supplement thyroid hormone and to inhibit the growth of DTC cells is an effort to decrease the risk of recurrence.
After the first (postoperative) application of 131 I therapy, the patient should be evaluated for the presence of remnants or metastases, which is important for submit your manuscript | www.dovepress.com
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Pan et al determining the necessity of repeated 131 I therapy. 4 Serum thyroglobulin (Tg) level is the most sensitive and specific indicator for monitoring DTC recurrence or metastases, but it cannot be used to locate the lesions or distinguish remnants from metastases; therefore, combining with other imaging methods is needed for evaluation. Ultrasonography and computed tomography are commonly used, but they have certain deficiencies for detecting functional TC recurrent or metastatic lesions, especially for the diagnosis of some minor metastatic lesions.
131 I imaging with diagnostic dose might not be able to detect small metastases and might induce a stunning effect (a reduction in the uptake of 131 I therapy dose induced by a pretreatment diagnostic activity) of remnants/ metastases, which might influence the efficacy of subsequent 131 I therapy.
5-8 99m TcO 4 -imaging 9 can provide information about the clearance of thyroid remnants, but it is not a tumorspecific imaging; therefore, it cannot be used to evaluate the clearance of TC metastases. Although 18 F-fluoro-2-deoxy-Dglucose positron emission tomography ( 18 FDG-PET) imaging can provide information about remnants and metastases with a high metabolism, it is too expensive for wider use in clinical application; besides, partial metastatic lesions (especially lymph node metastases) show no high intake of fluorodeoxyglucose.
10 99m Tc-methoxyisobutylisonitrile (MIBI) is a nonspecific tumor-philic imaging agent; it has been used for diagnosing and evaluating the efficacy of treatments for lung cancer, breast cancer, bone cancer, gliomas, and other malignant tumors. [11] [12] [13] [14] [15] [16] The present study compared the results of 99m Tc-MIBI imaging and therapeutic-dose 
Materials and methods clinical data
laboratory tests
By using the chemiluminescence method, the serum Tg level (reference value, ,35 ng/mL) was measured in all patients, both after they stopped the medication of thyroxin preparation 4 weeks prior to imaging and just before the imaging. The radioimmunoassay method was used to detect the levels of TSH (reference range, 0.3-5.0 mIU/L) and Tg antibody (TgAb, reference value, ,30%). 
Tc-MiBi imaging
Patients were intravenously injected with 740-925 MBq 99m Tc-MIBI (Beijing Xinke Co., Beijing, People's Republic of China), and then, neck and chest as well as systemic planar images were obtained after 90 minutes. A singlephoton emission computed tomography (SPECT)/computed tomography (CT) instrument (Symbia T2; Siemens, Munich, Germany) was used, which was equipped with a parallel low-energy high-resolution collimator with an energy peak of 140 keV and a window width of 20%. The magnification fold when performing neck and chest scanning was 1.5, with a matrix of 256×256 pixels and an acquisition count of 500 K. The magnification fold when performing systemic scanning was 1.0, with a matrix of 256×1,024 pixels and scanning speed of 15 cm/min. I imaging). A SPECT/CT instrument (Symbia T2) was used, which was equipped with a parallel low-energy high-resolution collimator with a matrix of 256×1,024 pixels, an energy peak of 364 keV, and a window width of 20%; the magnification fold was 1, with a scanning speed of 15 cm/min and acquisition count of 100-150 K.
image analysis
The images were evaluated independently by two physicians with SPECT/CT diagnostic experience. The images with consistent evaluation results were then included in the final analysis. Positive cases were defined as the presence of an abnormal radioactive uptake outside the thyroid gland bed area or the thyroid gland -as found on either of the abovementioned imaging methods -and negative cases were 
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Treating differentiated thyroid cancer defined as no imaging agent uptake outside the thyroid gland bed area and the thyroid gland. statistical analysis SPSS 13.0 software (SPSS Inc., Chicago, IL, USA) was used for the statistical analysis. The data were assessed using the chi-square test. The measurement data are expressed as x±s. The intergroup data were compared with an independent samples t-test, with P,0.05 considered statistically significant.
Results
imaging results of all patients
The imaging results of a total of 191 patients with DTC were included in the study (the images of one patient were excluded owing to considerable differences between the evaluation results of the two physicians Tc-MIBI imaging, and the liver, spleen, intestinal tract, heart, and bladder tissue have significant physiological uptake and (B) 131 i on rx-WBs imaging, showing the liver also has more 131 i uptake, and hence, we cannot exclude that this patient has liver metastases. Abbreviations: FTc, follicular thyroid carcinoma; MiBi, methoxyisobutylisonitrile; rx-WBs, high-dose 131 i whole body scan.
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Pan et al Tc-MIBI uptake in the thyroid gland bed area ( Table 2) .
results of serum Tg in each group
According to imaging results, all patients were classified into four groups: group I ( 99m Tc-MIBI negative and Tc-MIBI-positive group (group IV) was significantly higher than the 131 I-positive group (group III). All the groups exhibited TSH levels .30 mIU/L and TgAb levels within the reference range, indicating that the Tg results (Table 3) were not influenced by TgAb. 
Discussion
The evaluation of whether postoperative TC metastases exist in patients with DTC should be preferably performed after the first (postoperative) application of 131 I therapy (namely, ablation of the thyroid gland) because the existence of residual normal thyroid tissue might influence the 131 I uptake of metastases, thus leading to false-negative results. The search for an imaging method that can not only sensitively detect TC metastases but also objectively assess whether residual thyroid tissues in the neck are completely resolved is important for the follow-up treatment of patients with DTC. Tc-MIBI is a nonspecific tumor-philic imaging agent with good physicochemical properties and a low radiation absorbance dose; therefore, it can be administered in high doses. In recent years, Tc-MIBI imaging has been widely used for the diagnosis of TC, breast cancer, lung cancer, bone tumors, and other malignancies. 11-16 99m Tc-MIBI is absorbed into the cytoplasm by passive diffusion and then goes into mitochondria by active transportation. Tumor cells have a high number of mitochondria, active metabolism, and an increased local blood supply, and thus, they can absorb and temporarily retain more MIBI. This characteristic of fast uptake and relatively slow excretion is significantly different from the uptake and excretion pattern of benign cells. This is the reason why the tumor tissues can be easily identified. [17] [18] [19] Accordingly, as the active ratio of the target tumor tissues to nontarget tissues is higher on delayed 99m Tc-MIBI imaging, the delayed imaging is more obvious; therefore, this study only analyzed the results in the delayed phase.
The use of 99m Tc-MIBI as a radioactive tracer has the following advantages in evaluating the existence of remnants and metastases in patients with DTC after surgery and the first application of 131 I therapy: ideal physical properties of 99m Tc-MIBI led to less radiation damage in patients and are suitable for SPECT imaging; is easily prepared and has low production cost; does not get affected by the serum TSH level, no need for long-term withdrawal of levothyroxine before imaging and avoids hypothyroid symptoms; its uptake is related to the contents and metabolism of intracellular mitochondria (both functional and nonfunctional metastases can ingest 99m Tc-MIBI, which could overcome the limitation of misdiagnosis of nonfunctional or dedifferentiated TC metastases of 131 I imaging); and is without the "stunning" effect and does not affect the efficacy of subsequent 131 I therapy.
As the most common metastatic areas of TC are the neck and chest, our department normally acquires neck and chest images (enlarged 1.5 times) and systemic images, which are helpful to discover the neck or lung metastases and provide information about iliac or other metastases. Tc-MIBI is excreted through the hepatobiliary system, which leads to obvious accumulation in the liver and intestines. Therefore, plain 99m Tc-MIBI scanning has substantial limitations in assessing metastases in the spine, gastrointestinal tract, and other organs. Figure 1 shows that systemic 99m Tc-MIBI imaging revealed lesions with an abnormal 99m Tc-MIBI uptake in the right iliac region of a patient.
131
I imaging also exhibited uptake in this site, so it might be considered an iliac metastasis; furthermore, as more 131 I uptake was seen in the liver, we could not exclude the possibility that the lesion was accompanied by liver metastasis. While even 99m Tc-MIBI imaging exhibits obvious aggregation in the liver and intestinal tract, it cannot be used to assess the possibility of liver metastasis.
Among the 65 positive cases found in this study, 131 I imaging could detect 60 cases (92.3%) and 99m Tc-MIBI imaging could detect 37 cases (56.9%). The positive rate on 
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Treating differentiated thyroid cancer 99m Tc-MIBI imaging was only 39.5%, which is significantly lower than that of 131 I imaging (P,0.01). This difference might be explained owing to the following reasons: after surgery and the first application of 131 I therapy, residual normal thyroid tissues are rare, the number of mitochondria in the normal cells is lower, and surgical trauma affects the local blood supply, all of these reasons lead to no or reduced 99m Tc-MIBI uptake. Therefore, the use of 99m Tc-MIBI imaging in assessing the existence of cervical residual normal thyroid tissues is very limited, and it cannot be used on its own to assess the existence of residual thyroid tissues.
A study has shown that, although 99m Tc-MIBI is a nonspecific tracer for TC, it has a high sensitivity and specificity in the detection of functional and nonfunctional metastases. 20 Rubello et al 21 I negative (the result of one patient is shown in Figure 2 ). We thought that the possible reasons for this difference might be dedifferentiation or poor differentiation of TC metastases. It is a pity that not one of them had the pathological examination of the metastatic lesions; therefore, the final reason is not clear. For these patients, the efficacy of routine 131 I therapy might be poor and other treatment options should be performed. Another two patients' metastatic lesions show a result of 131 I positive but 99m Tc-MIBI negative, which might be due to the lower mitochondria content in tumor cells, but the exact reason is still not clear.
Tg is synthesized by thyroid follicular cells. The serum Tg level was a specific marker for monitoring residual tumor cells, recurrence, and metastasis of DTC and for assessing the efficacy of treatment. In patients who underwent total thyroidectomy and who had already been treated with 131 I ablation of the thyroid gland, the serum Tg levels should be below the reference line or undetectable; therefore, an increase in Tg might suggest a recurrence or metastasis of TC. In this study, the TgAb levels of all patients were within the reference range, indicating that antibodies did not interfere with the Tg results. The serum Tg level of the positive group was significantly higher than that of the negative group, indicating that the imaging results had good correlations with the Tg levels, consistent with previous reports. 23 We noted that the survival rate and the reliability of Tg as a tumor marker during the follow-up period were directly influenced by whether 
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